Genocea Biosciences Inc Shares outstanding
What is the Shares outstanding of Genocea Biosciences Inc?
The Shares outstanding of Genocea Biosciences Inc is 58.784M
What is the definition of Shares outstanding?
Shares outstanding are all the shares of a corporation or of a financial asset that have been authorized, issued and purchased by investors and are held by them.
= issued shares - treasury shares
Shares outstanding includes all stock held by investors including both common shares held by the public and restricted shares owned by the company's internal managements. Shares outstanding have rights and represent an ownership in the corporation by the person who holds the shares. They are distinguished from treasury shares, which are shares held by the corporation itself and have no exercisable rights. Shares outstanding plus treasury shares together amount to the number of issued shares.
Shares outstanding can be calculated as either basic or fully diluted. The basic count is the current number of shares. Dividend distributions and voting in the general meeting of shareholders are calculated according to this number. The fully diluted shares outstanding count, on the other hand, includes diluting securities, such as warrants, capital notes or convertibles. If the company has any diluting securities, this indicates the potential future increased number of shares outstanding. A company's market capitalization is calculated by multiplying the price of one of its shares by the total number outstanding shares a company has issued.
Shares outstanding of companies in the Health Care sector on NASDAQ compared to Genocea Biosciences Inc
What does Genocea Biosciences Inc do?
Genocea's mission is to conquer cancer by developing personalized cancer immunotherapies in multiple tumor types. Our unique ATLAS™ platform comprehensively profiles each patient's T cell responses to potential targets, or antigens, on the tumor. ATLAS enables us to optimize the neoantigens for inclusion in our immunotherapies and exclude inhibitory antigens, Inhibigens™, that can exert an immunosuppressive effect. We are advancing two ATLAS-enabled programs: GEN-009, our neoantigen vaccine and GEN-011, our neoantigen-specific cell therapy using T cells derived from peripheral blood.
Companies with shares outstanding similar to Genocea Biosciences Inc
- IOL Chemicals and Pharmaceuticals has Shares outstanding of 58.706M
- IOL Chemicals and Pharmaceuticals has Shares outstanding of 58.706M
- Invesco Asia Trust Plc has Shares outstanding of 58.707M
- Cyon Exploration has Shares outstanding of 58.725M
- Teleperformance SE has Shares outstanding of 58.733M
- Clifton Mining Co has Shares outstanding of 58.771M
- Genocea Biosciences Inc has Shares outstanding of 58.784M
- Jiulian Resources has Shares outstanding of 58.787M
- B.C. Power Controls has Shares outstanding of 58.800M
- B.C. Power Controls has Shares outstanding of 58.800M
- Iliad SA has Shares outstanding of 58.818M
- GTT Communications Inc has Shares outstanding of 58.820M
- California Water Service has Shares outstanding of 58.825M